ASAHI RUBBER INC.
5162・Standard Market・Rubber Products
Business
Asahi Rubber Inc., founded in 1970, is a precision rubber products manufacturer operating two segments: the Industrial Rubber Business and the Medical & Sanitary Rubber Business. In the Industrial Rubber Business, the company manufactures and sells ASA COLOR LED for automotive interior lighting, Precision Rubber Products (O-rings, Switch Components, etc.) for control systems, Table Tennis Racket Rubber, and Rubber Products for RFID Tags, among others. In the Medical & Sanitary Rubber Business, the company handles Rubber Stoppers for Blood Collection and Drug Admixture, Medical Check Valves, Prefilled Syringe Gaskets, Rubber Components for Medical Procedure Simulators, and more. In addition to domestic plants (Saitama, Fukushima, Shirakawa), the company has subsidiaries in China, Hong Kong, and North America, building a global supply structure. Major customers include leading manufacturers such as Alps Alpine, Nichia Corporation, and Tamasu (Butterfly).
Business Model
The Industrial Rubber Business accounts for roughly 76% of net sales, while the Medical & Sanitary Rubber Business accounts for roughly 24%. Historically the company was centered on OEM manufacturing based on customer specifications, but it is now promoting a shift toward ODM, in which it handles everything from design and development through to manufacturing, leveraging its three core technologies: "color and light control technology," "material modification technology," and "surface modification/micro-processing technology." Capital expenditures are funded mainly through long-term borrowings and operating cash flow, with liquidity secured via a ¥1 billion commitment line agreement.
Company Strengths
The company possesses three core technologies—'color and light control technology,' 'material modification technology,' and 'surface modification/micro-processing technology'—and achieves high value-added products by combining and fusing these. ASA COLOR LENS has been adopted for use on the International Space Station (ISS), and adoption in automotive applications leveraging siloxane removal technology is also expanding, demonstrating that the uniqueness of its technology has earned the trust of customers.
In FY2026 (ending March 2026), the company recorded sales of ¥5,947 million in the Industrial Rubber Business and ¥1,905 million in the Medical & Sanitary Rubber Business, operating with these two segments. The Medical & Sanitary Rubber Business achieved record-high sales in FY2026 (ending March 2026), driven by expanded orders for Rubber Stoppers for Blood Collection and Drug Admixture, as well as contributions from in-house developed products such as Medical Check Valves and medical procedure simulators. This structure allows the medical business to offset fluctuation risk in the Industrial Rubber Business.
In addition to multiple domestic plants (Saitama, Fukushima, Shirakawa), the company has established subsidiaries in China (Dongguan and Shanghai), Hong Kong, and North America (Asahi Crosslink Corporation). In the Industrial Rubber Business, Dongguan Asahi Precision Rubber Products Co., Ltd. handles sales to China, while Asahi Crosslink Corporation handles sales to Europe and the US. In the medical business, Asahi Front Medic, established in August 2024, has obtained a medical device sales license and is strengthening the domestic sales structure.
ENVALITH's Perspective
Performance Trend
Revenue has continued a gradual growth trend, rising from ¥7,024 million in FY2022 (ended March 2022) to ¥7,852 million in FY2026 (ending March 2026). On the profit side, FY2025 (ended March 2025) saw a sharp deterioration, with operating profit of ¥2 million and net loss of ¥236 million, due to factors including the recording of an impairment loss of ¥288 million. However, in FY2026 (ending March 2026), extraordinary losses narrowed to just ¥7 million in loss on disposal of fixed assets, and the gross profit margin improved (cost of sales ratio improved to 76.4% from 79.0% in the prior period), resulting in a return to profitability with operating profit of ¥197 million and net income of ¥158 million. However, the forecast for FY2027 (ending March 2027) anticipates revenue of ¥8,172 million (up 4.1% year on year) but operating profit of ¥148 million (down 25.2% year on year), indicating profits are expected to decline again. Global inflation, yen depreciation-driven increases in resource prices, and geopolitical risks continue to exist as external factors pressuring earnings.
Growth Strategy
Aiming for growth across four businesses and ¥10 billion in sales with a 5% operating margin, centered on wellness branding
A five-year plan under the theme "Beyond 2030" will begin in April 2026. The company will consolidate added value as "wellness" across the four markets of mobility, healthcare, sports & health, and daily life, setting quantitative targets of consolidated net sales of ¥10 billion or more and a consolidated operating margin of 5% or more.
Continuing to drive increased orders for Rubber Stoppers for Blood Collection and Drug Admixture, Medical Check Valves, and medical simulators. Order growth is expected to continue into FY2027 (ending March 2027). Sales reached ¥1,905 million in FY2026 (ending March 2026), up 7.9% year on year, maintaining growth momentum, though segment profit margin has declined, making product mix improvement a key challenge.
Continuing to build new production capacity and pursue rationalization investment to expand orders for Precision Rubber Products (O-rings, Switch Components, etc.) for automotive applications and Table Tennis Racket Rubber. Segment profit in FY2026 (ending March 2026) rebounded sharply to ¥305 million, up 165.8% year on year, with the investment effects partly materializing.
Promoting a shift from contract manufacturing based on customer specifications to ODM, in which the company handles its own design and development, thereby increasing the proportion of high-value-added products leveraging its three core technologies. The company also utilizes collaboration with external resources to improve profitability across its four businesses.
Introduced a new stock-granting ESOP trust starting in FY2026 (ending March 2026). The scheme is designed to raise employees' stock-price awareness and work motivation, functioning as an incentive program that strengthens their commitment to improving medium- to long-term business performance and increasing corporate value. As of the end of the consolidated fiscal year, the trust held 96,600 shares (book value of ¥69 million).
Last updated: July 19, 2026